Moreover, FAP-specific modification of CAR T cells can contribute to the depletion of FAP-expressing stromal cells and inhibit tumor growth by promoting the production of immunostimulatory cytokines, inducing tumor cell lysis, enhancing the anti-tumor response of endogenous CD8+ T cells, and favoring the anti-tumor effects of α-CTLA-4 and α-PD-L1 therapy. The gene discussed is CD8A; the disease is neoplasm.